FLOR-EN Baby
Pediatrics
- Reduces mucosal inflammation
- Helps restore intestinal barrier function
- Counteracts gut dysbiosis
- Reduces prevalence and duration of antibiotic-associated diarrhea






Limosilactobacillus reuteri LRE02 (DSM 23878)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)
Food supplement with probiotic strains.
Vitamin D
EFSA Claim: contributes to the normal function of the immune system; has a role in the process of cell division
Biotin
EFSA Claim: contributes to the mantainance of normal skin and mucosa
FLOR-EN® Baby is an allergen-free, clean-label formulation specifically designed for infants and children. Presented in an oil suspension, it targets infant dysbiosis and antibiotic-associated diarrhea. The formulation includes two probiotic strains, Limosilactobacillus reuteri LRE02 and Lacticaseibacillus rhamnosus LR04, which are effective in:
Preventing damage to gut epithelium integrity and restoring the membrane after damage [1].
Modulating the immune response against pathogens by significantly increasing natural killer cell activity [2].
Directly inhibiting various pathogenic microorganisms, including multiple strains of pathogenic E. coli, as well as Enterococcus faecalis, Klebsiella pneumoniae, E. coli, and Staphylococcus aureus, attributed to genes coding for bacteriocins [3,4].
In a clinical study, daily supplementation with 5 drops of FLOR-EN® Baby for 30 days in children undergoing treatment with penicillins, cephalosporins, and macrolides significantly reduced the prevalence of antibiotic-associated diarrhea. It also improved stool consistency and decreased the number of days with diarrhea. Notably, there were significant differences in the prevalence of antibiotic-associated diarrhea among the three antibiotic categories between the two groups (p<0.0001) [5].
1. Internal Probiotical data
2. Chamignon C, et al. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms. 2020 Jul 15;8(7):1053 doi: 10.3390/microorganisms8071053.
3. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7
4. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216. DOI: 10.35248/2329-8901.20.8.216
5. Drago L, et al. Effect of LimosiLactobacillus reuteri LRE02-Lacticaseibacillus rhamnosus LR04 Combination on Antibiotic- Associated Diarrhea in a Pediatric Population: A National Survey. J Clin Med. 2020 Sep 24;9(10):E3080. DOI: 10.3390/jcm9103080